Urologic Neoplasms

Oncology
3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 2 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Achieve Life Sciences
2 programs
2
OGX-427 600 mgPhase 21 trial
S-8184 Paclitaxel Injectable EmulsionPhase 21 trial
Active Trials
NCT01454089CompletedEst. Nov 2014
NCT00034177CompletedEst. Sep 2007
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
AfatinibPhase 2Small Molecule1 trial
Active Trials
NCT02780687Completed42Est. Sep 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Boehringer IngelheimAfatinib
Achieve Life SciencesOGX-427 600 mg
Achieve Life SciencesS-8184 Paclitaxel Injectable Emulsion

Clinical Trials (3)

Total enrollment: 42 patients across 3 trials

Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy

Start: Jun 2016Est. completion: Sep 201942 patients
Phase 2Completed

A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Start: Oct 2011Est. completion: Nov 2014
Phase 2Completed
NCT00034177Achieve Life SciencesS-8184 Paclitaxel Injectable Emulsion

Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium

Start: Apr 2002Est. completion: Sep 2007
Phase 2Completed

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space